Zobair M. Younossi, Radhika Tampi, Massoom Priyadarshini, Fatema Nader, Issah M. Younossi, Andrei Racila – 4 September 2018 – Nonalcoholic steatohepatitis (NASH) is the progressive form of nonalcoholic fatty liver disease. Our aim was to estimate the total economic burden of NASH and advanced NASH in the United States. We constructed lifetime Markov models for all stages of NASH and a separate model to specifically identify the increased burden of advanced NASH (fibrosis stage >3). The models comprised patients aged 18+, who moved through seven different health states.

Jingwen Wang, Jianwen Chen, Yang Liu, Xianhuang Zeng, Mingcong Wei, Shaoshuai Wu, Qiushuang Xiong, Feifei Song, Xu Yuan, Yu Xiao, Yun Cao, Changyong Li, Lang Chen, Mingxiong Guo, Yun‐Bo Shi, Guihong Sun, Deyin Guo – 4 September 2018 – Hepatitis B virus (HBV) is a major risk factor for the development and progression of hepatocellular carcinoma. It has been reported that viral infection can interfere with cellular microRNA (miRNA) expression and participate in the pathogenesis of oncogenicity.

Binita Kamath, Cara Mack – 4 September 2018

Wei‐Yu Kao, Chien‐Wei Su, Elise Chia‐Hui Tan, Pei‐Chang Lee, Ping‐Hsien Chen, Jui‐Hsiang Tang, Yi‐Hsiang Huang, Teh‐Ia Huo, Chun‐Chao Chang, Ming‐Chih Hou, Han‐Chieh Lin, Jaw‐Ching Wu – 2 September 2018 – Researchers have hypothesized that the long‐term use of proton pump inhibitors (PPIs) can increase the risk of developing cancer. However, the association between PPI use and hepatocellular carcinoma (HCC) risk is unclear.

Mindie H. Nguyen, Joseph K. Lim, A. Burak Ozbay, Jeremy Fraysse, Iris Liou, Nicole Meyer, Geoffrey Dusheiko, Stuart C. Gordon – 2 September 2018 – Chronic hepatitis B (CHB) comorbidity data are limited. Using insurance claims databases, our aims were to determine the prevalence and incidence of nonliver comorbidities in CHB patients over time and the predictors of select comorbidities in CHB patients. Patients were adults with continuous coverage (commercial/Medicare or Medicaid) 6 months prior to and after the first CHB diagnosis and matched non‐CHB patients.

Winston Dunn, Naga Chalasani – 2 September 2018

Yongjun Tian, Jing‐hsiung James Ou – 31 August 2018

Fien A. von Meijenfeldt, Laura C. Burlage, Sarah Bos, Jelle Adelmeijer, Robert J. Porte, Ton Lisman – 31 August 2018 – Patients undergoing liver transplantation have complex changes in their hemostatic system, and the net effect of these changes appears to be a “rebalanced” hemostatic profile. Recently, a process called NETosis in which a neutrophil expels DNA and proteins that form a weblike structure, has been described as a mechanism of pathogen entrapment.

John B. Kisiel, Brian A. Dukek, Reddappa V.S.R. Kanipakam, Hassan M. Ghoz, Tracy C. Yab, Calise K. Berger, William R. Taylor, Patrick H. Foote, Nasra H. Giama, Kristeen Onyirioha, Mohamed A. Abdallah, Kelli N. Burger, Seth W. Slettedahl, Douglas W. Mahoney, Thomas C. Smyrk, Jason T. Lewis, Maria Giakoumopoulos, Hatim T. Allawi, Graham P. Lidgard, Lewis R. Roberts, David A. Ahlquist – 31 August 2018 – Early detection improves hepatocellular carcinoma (HCC) outcomes, but better noninvasive surveillance tools are needed.

Marlyn J. Mayo, Alan J. Wigg, Barbara A. Leggett, Hays Arnold, Alexander J. Thompson, Martin Weltman, Elizabeth J. Carey, Andrew J. Muir, Lei Ling, Stephen J. Rossi, Alex M. DePaoli – 30 August 2018 – Patients with primary biliary cholangitis (PBC) who had an inadequate response to ursodiol have few treatment options. Alkaline phosphatase (ALP) and bilirubin levels correlate with the risk of liver transplant or death in PBC patients. Fibroblast growth factor (FGF) 19 is a hormone that acts directly in the liver to regulate bile acid synthesis.